Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 35, 2008, Pages 13157-13162

  Chou, Ting Chao ^a   Zhang, Xiuguo ^a   Zhong, Zi Yang ^c   Li, Yong ^c   Feng, Li ^c   Eng, Sara ^c   Myles, David R ^c   Johnson Jr , Robert ^c   Wu, Nian ^a   Yin, Ye Ingrid ^a   Wilson, Rebecca M ^a   Danishefsky, Samuel J ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c KOSAN BIOSCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12,13 DESOXY EPOTHILONE B; CAPECITABINE; CARMUSTINE; DEHYDELONE; DOCETAXEL; EPOTHILONE DERIVATIVE; FLUDELONE; ISODEHYDELONE; ISOFLUDELONE; PACLITAXEL; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINBLASTINE; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; FEMALE; HUMAN; HUMAN CELL; LOW DRUG DOSE; LUNG CARCINOMA; MICROTUBULE; MOUSE; NEUROBLASTOMA; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; PRIORITY JOURNAL; THERAPY EFFECT; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; CELL PROLIFERATION; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; FEMALE; HUMANS; MICE; MICE, NUDE; MICROTUBULES; NEOPLASMS; TUBULIN MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MAMMARIA; MUS MUSCULUS;

EID: 51349140042     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0804773105     Document Type: Article

References (13)

1. Wilson RM, Danishefsky SJ (2006) Small molecule natural products in the discovery of therapeutic agents: The synthesis connection. J Org Chem 71:8329-8351.
2. Gerth K, Bedorf N, Höfle G, Irschik H, Reichenbach H (1996) Epothilones A and B: Antifungal and cytotoxic compounds from Sorangium cellulosum (myxobacteria) - Production, physico-chemical and biological properties. J Antibiot 49:560-563.
3. Bollag DM, et al. (1995) Epothilones: A new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55:2325-2333.
4. Balog A, et al. (1996) Total synthesis of (--)-epothilone A. Angew Chem Int Ed 35:2801-2803.
5. Su D-S, et al. (1997) Total synthesis of (--)-epothilone B: An extension of the Suzuki coupling method and insights into structure - Activity relationships of the epothilones. Angew Chem Int Ed 36:757-759.
6. Chou T-C, et al. (1998) Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc Natl Acad Sci USA 95:9642-9647.
7. Chou T-C, et al. (1998) Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc Natl Acad Sci USA 95:15798-15802.
8. Chou T-C, et al. The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proc Natl Acad Sci USA 98:8113-8118, 2001.
9. Rivkin A, Chou T-C, Danishefsky SJ (2005) On the remarkable properties of fludelone: How we got there. Angew Chem Int Ed 44:2838-2850.
10. Rivkin A, et al. (2004) Discovery of (E)-9,10- dehydroepothilones through chemical synthesis: On the emergence of 26-trifluoro-(E)-9,10-dehydro-12,13-desoxyepothilone B as a promising anticancer drug candidate. J Am Chem Soc 126:10913-10922.
11. Chou T-C, Dong H, Zhang X, Tong WP, Danishefsky SJ (2005) Therapeutic cure against human tumor xenografts in nude mice by a microtubule stablilization agent, fludelone, via parental or oral route. Cancer Res 65:9445-9454.
12. Cho YS, Wu K, Moore MAS, Chou T-C, Danishefsky SJ (2005) Second-generation epothilones: Discovery of fludelone and its extraordinary antitumor properties. Drugs of the Future 30:737-745.
13. Zhang Z, et al. (2007) KOS: A new, rationally designed epothilone analog with an improved pharmacological profile and efficacy in xenograft mouse models. Proc Am Assoc Cancer Res 48:341.